If you have diabetes, your doctor might suggest Tresiba (insulin degludec) as a treatment option for you. Tresiba is a prescription medication. It’s used long term to manage blood sugar levels in ...

Tresiba and Lantus are both long-acting insulins used to manage blood sugar levels in people with type 1 or type 2 diabetes. (For more information on each’s drug uses, see the “What are Tresiba and ...

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinions, recommending marketing authorisations, ...

Tresiba (insulin degludec) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat type 1 and type 2 diabetes in ...

Bagsværd, Denmark, 29 January 2016 - Novo Nordisk today announced the headline results from SWITCH 2, the first of two 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials, ...

Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in A1C and a 30% lower rate of hypoglycaemic episodes after starting basal insulin This ...

Vienna, Austria, 16 September - Today, at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), Novo Nordisk announced new data from the BEGIN® YOUNG 1 trial. The study ...

Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Tresiba® (insulin degludec) for the treatment of diabetes. Tresiba® is a new generation of once-daily ...

Novo Nordisk, a global healthcare company, has launched Tresiba (insulin degludec) in Denmark for people with type 1 and type 2 diabetes. Tresiba is indicated for the treatment of diabetes mellitus in ...

As with other drugs, Tresiba (insulin degludec) can cause side effects, such as headache, upper respiratory infection, and injection site reaction. If side effects of Tresiba become difficult to ...